LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million

First exit for LifeArc Ventures, the largest investor in Ducentis, recognising the transformational potential of its scienceDucentis lead pre-clinical asset DS-234 is being developed for the

Related Keywords

California ,United States ,London ,City Of ,United Kingdom ,Clare Terlouw ,Prnewswire Lifearc ,Philip Huxley ,Mo Noonan Jonathan Birt ,Maria Tennant ,Ceoof Ducentis ,Frank Watanabe ,Janet Morgan ,Arcutisbiotherapeutics Inc ,Nasdaq ,Lifearc Ventures ,Lifearc Venture ,Arcuti President ,Chief Executive ,Lifearc ,Portfolio ,Company ,Lucentis ,Iotherapeutics ,Cquired ,Arcutis ,Billion ,